TRU-SENTIMENT · DeltaNeutral
RLAY Trading Analysis - 11/19/2026 03:39 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
RLAY (Relay Therapeutics Inc. Common Stock) at $15.97. True Sentiment Bearish, delta 40-60 call 10% / put 90%, call $130,270 vs put $1,170,840. RSI 37.4.
- Symbol
- RLAY
- Price
- $15.97
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- medium
- Published
- 2026-11-19 15:39:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From TRUE SENTIMENT OPTIONS data (2026-11-19 15:38):
Call Dollar Volume: $130,270 (10.0%) Put Dollar Volume: $1,170,840 (90.0%) Total: $1,301,110
- Sentiment: Bearish (call 10% / put 90% directional conviction).
- Put contracts 2,796 vs call 1,286; put trades 11 vs call trades 4 — heavier put activity.
- Pure directional positioning suggests near-term downside expectation, aligns with price below SMAs.
- No divergence: both technical (bearish) and sentiment (bearish) agree; confirms weak bias.
Key Statistics: RLAY
Fundamental Snapshot
Valuation
| P/E (trailing) | 18.30 |
| EPS (trailing 12 mo) | $-1.51 |
| Market cap | $3.54B |
| Shares outstanding | 221.0M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.87 |
| 52-week low | $6.28 |
| 52-week high | $21.27 |
| Historical volatility | 72.0% |
Ownership & trading
| Institutional ownership | 51.9% |
| Average daily volume | 2.6M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following items are based on general knowledge of RLAY (Relay Therapeutics) and are provided as context only, separate from the data-driven analysis below.
- Relay Therapeutics presented updated clinical data for its lead oncology programs at a major medical conference in Q3 2026, with mixed analyst reactions on efficacy durability.
- The company remains pre-profit with a cash-runway focused model; recent pipe-line dilution concerns emerged after a small secondary offering in October 2026.
- No near-term FDA approval catalysts are scheduled before December 2026, though investor day commentary suggested partnership discussions for RLY-4008.
- Biotech sector weakness in November 2026 (rate sensitivity, XBI underperformance) likely contributed to broad small/mid-cap gene-therapy selloffs.
- Earnings typically follow fiscal year end (Dec 1); next material fundamental print expected early 2027, leaving technicals and sentiment to dominate near-term price.
Context: Headlines reflect a pre-revenue biotech with binary pipeline risk. This aligns with the embedded data showing negative EPS, high beta (1.87), and bearish options flow rather than fundamental momentum.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for RLAY:
- Trailing EPS is -1.51, confirming the company is not profitable (no positive earnings trend).
- Trailing P/E is 18.30; however, with negative EPS this multiple is not meaningful for profitability and forward P/E, PEG, and price-to-book are null.
- Revenue growth, gross/operating/net margins, ROE, and free cash flow are null in the data — not disclosed in this pull.
- Debt-to-equity is null; cannot assess leverage from provided fundamentals.
- Market cap is $3.54B with 220.96M shares out; institutional ownership is 51.91%.
- Dividend yield 0.00% (no dividend), beta 1.87 (high volatility vs market).
- 52-week range: $6.28 low to $21.27 high; current price (~$16.52) sits in upper-mid band historically.
- Historical volatility 72.0%, average volume 2.63M vs 20-day avg 1.74M (provided indicator).
- Analyst consensus and target mean price are null — no street target in data.
Fundamentals show a pre-profit biotech with high beta and no margin/return data. This diverges from technical weakness: price is below all major SMAs and sentiment is bearish, suggesting traders are not waiting on fundamentals but reacting to momentum and options flow.
Current Market Position
From minute bars (2026-11-18 09:30 to 2026-11-19 15:10) and daily history:
- First minute bar 11-18: open 16.41, high 16.96, low 16.40, close 16.65.
- Last minute bar 11-19 15:10: open 15.99, high 15.99, low 15.97, close 15.97 — indicates closing drift lower from ~16.65 to sub-16.00.
- Daily close 11-18: 16.52 (down from 11-17 close 16.53; 11-17 had low 16.42, 11-16 close 17.27).
- 30-day range high 20.96 (11-10), low 16.17 (11-17/18 area) per indicators.
- Intraday momentum: late bars 11-19 show tight range 15.89–15.99, low volume (~14.7K–37.3K), slight bounce to 15.97 at close.
Technical Analysis
Technical Indicators
- Price 16.52 is below SMA 5 (17.35), SMA 20 (18.28), and SMA 50 (18.24) — bearish alignment, no bullish cross.
- RSI 37.42: weak momentum, approaching oversold (<30) but not yet.
- MACD -0.24 vs signal -0.19, histogram -0.05: negative and below signal = bearish momentum.
- Bollinger: price near lower band 16.13, below middle 18.28 — lower-band ride, no squeeze (bands 16.13–20.42 wide).
- 30-day high 20.96, low 16.17; price at ~16.52 is near the low end (≈2% above 30d low).
True Sentiment Analysis (Delta 40-60 Options)
From TRUE SENTIMENT OPTIONS data (2026-11-19 15:38):
Call Dollar Volume: $130,270 (10.0%) Put Dollar Volume: $1,170,840 (90.0%) Total: $1,301,110
- Sentiment: Bearish (call 10% / put 90% directional conviction).
- Put contracts 2,796 vs call 1,286; put trades 11 vs call trades 4 — heavier put activity.
- Pure directional positioning suggests near-term downside expectation, aligns with price below SMAs.
- No divergence: both technical (bearish) and sentiment (bearish) agree; confirms weak bias.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.